1/6/2010 2:12:08 PM
London, UK 5 January 2010 Silence Therapeutics plc ("the Company") (AIM: SLN)
and Intradigm Corporation announce that the companies have completed their
merger to form a leading company in the field of RNAi (RNA interference). The
enlarged company, named Silence Therapeutics, possesses multiple RNAi
discovery, development and delivery technologies, an advancing internal and
partnered product pipeline and a broad portfolio of intellectual property. The
merged company believes that its expanded business will facilitate more deals
of greater value with the pharmaceutical industry by offering potential
partners a choice of technologies to deliver RNAi molecules to diseased tissue.
Additionally, Silence Therapeutics will actively develop and advance its own
RNAi therapeutic candidates.
comments powered by